



(12) Translation of
European patent specification

(11) NO/EP 2867240 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 495/04 (2006.01)
A61K 31/4365 (2006.01)
A61P 3/10 (2006.01)

Norwegian Industrial Property Office


(21)	Translation Published	2016.12.12
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.09.14
(86)	European Application Nr.	13732533.8
(86)	European Filing Date	2013.06.28
(87)	The European Application's Publication Date	2015.05.06
(30)	Priority	2012.06.29, EP, 12305775
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	Poxel, Immeuble le Sunway 259/261 avenue Jean Jaures, 69007 Lyon, FR-Frankrike
(72)	Inventor	CRAVO, Daniel, 18 bis chemin des Murgers, F-78360 Montesson, FR-Frankrike HALLAKOU-BOZEC, Sophie, 63 ter, rue des Hautes Bièvres, F-92160 Antony, FR-Frankrike BOLZE, Sébastien, 382 chemin des Dorriers, F-01600 Massieux, FR-Frankrike LEPIFRE, Franck, 3 rue Arthur Rimbaud, F-91400 Saclay, FR-Frankrike FAVERIEL, Laurent, 27 rue Copernic, F-91160 Longjumeau, FR-Frankrike DURAND, Jean-Denis, 85 rue de Paris, F-93100 Montreuil-sous-Bois, FR-Frankrike CHARON, Christine, 1 chemin de la Justice, F-91940 Gometz-le-Châtel, FR-Frankrike
(74)	Agent or Attorney	Bryn Aarflot AS, Postboks 449 Sentrum, 0104 OSLO, Norge

(54)	Title	THIENOPYRIDONE DERIVATIVES USEFUL AS ACTIVATORS OF AMPK
(56)	References Cited:	WO-A1-2009/124636 US-B2- 7 119 205

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse med formel (1)



karakterisert ved at:

R1 representerer et hydrogenatom eller et halogenatom;

R2 representerer en indanyl- eller tetralinyl gruppe substituert eller ikke med én eller flere grupper valgt fra halogenatomer, alkylgrupper, hydroksygrupper, alkoksygrupper, amino-, mono- eller di-alkylaminogrunder, karboksygrupper, alkylloksykarbonylgrupper, mono- eller di-alkylaminokarbonylgrupper, karboksamid, cyano, alkylsulfonyl og trifluormetylgrupper;

R3 representerer en aryl eller heteroaryl-gruppe, substituert eller ikke med en eller flere atomer eller grupper valgt fra halogenatomer, alkylgrupper, hydroksygrupper, alkoksygrupper, aralkyloksygrupper, amino, mono- eller di-alkylaminogrunder, karboksygrupper, alkylloksykarbonylgrupper, mono- eller di-alkylaminokarbonylgrupper, karboksamid, cyano, alkylsulfonyl og trifluormetylgrupper;

eller en geometrisk isomer, tautomer, epimer, enantiomer, stereoisomer, diastereoisomer racemat,

farmasøytisk akseptabelt salt eller solvat derav,

som er valgt fra gruppen bestående av:

2-klor-4-hydroksy-3-indan-5-yl-5-fenyl-7H-tieno [2,3-b] pyridin-6-on

2-klor-5- (4-fluorfenyl) -4-hydroksy-3-indan-5-yl-7H-tieno [2,3-b] pyridin-6-on

2-klor-4-hydroksy-3-indan-5-yl-5- (3-metoksyfenyl) -7H-tieno [2,3-b] pyridin-6-on

2-klor-4-hydroksy-3-indan-5-yl-5- (4-metoksyfenyl) -7H-tieno [2,3-b] pyridin-6-on

3- (2-klor-4-hydroksy-3-indan-5-yl-6-okso-7H-tieno [2,3-b] pyridin-5-yl) benzonitril

2-klor-4-hydroksy-3- -indan-5-yl-5- (3-metylphenyl) -7H-tieno [2,3-b] pyridin-6-on

2-klor-5- (4-fluorfenyl) -4-hydroksy-3- (4-hydroxyindan-5-yl) -7H-tieno [2,3-b] pyridin-6-on

2-klor-5- (3-fluorfenyl)-4-hydroksy-3-(4-hydroxyindan-5-yl) -7H-tieno [2,3-b] pyridin-6-on

2-klor-4-hydroksy-3-indan-5-yl-5-(3-pyridyl) -7H-tieno [2,3-b] pyridin-6-on

2-klor-4-hydroksy-3- (4-hydroksyindan-5-yl) -5-fenyl-7H-tieno [2,3-b] pyridin-6-on
 2-klor-5- (2-fluorfenyl) -4-hydroksy-3- (4-hydroksyindan-5-yl) -7H-tieno [2,3-b]
 pyridin-6-on
 2-klor-4-hydroksy-3- (5-hydroksytetralin-6-yl) -5-fenyl-7H-tieno [2,3-b] pyridin-6-on
 3- (2-klor-4-hydroksy-6 -okso-3-tetralin-6-yl-7H-tieno [2,3-b] pyridin-5-yl) benzonitril
 2-klor-4-hydroksy-5- (3-pyridyl) -3-tetralin-6- yl-7H-tieno [2,3-b] pyridin-6-on
 trinatrium 2-klor-3- (5-oxidotetralin-6-yl) -5-fenyl-tieno [2,3-b] pyridin-4, 6-diolat
 2-klor-4-hydroksy-5-fenyl-3-tetralin-6-yl-7H-tieno [2,3-b] pyridin-6-on
 2-klor-5-(4-fluorfenyl)-4-hydroksy-3-(5-hydroksytetralin-6-yl) -7H-tieno [2,3-b]
 pyridin-6-on
 dinatrium 2-klor-3- (5-oxidotetralin-6-yl) -6- okso-5-fenyl-7H-tieno [2,3-b] pyridin-4-
 olat
 2-klor-4-hydroksy-3-(5-hydroksytetralin-6-yl)-5-(3-metylfenyl)-7H-tieno [2,3-b]
 pyridin-6-on
 2-klor-4-hydroksy-3-(5-hydroksytetralin-6-yl)-5-(4-metylfenyl)-7H-tieno [2,3-b]
 pyridin-6-on
 2-klor-5-(3-fluorfenyl)-4-hydroksy-3-(5-hydroksytetralin-6-yl) -7H-tieno [2,3-b]
 pyridin-6-on
 natrium-2-klor-3- (5-hydroksytetralin-6-yl) -6-okso-5-fenyl-7H-tieno [2,3-b] pyridin-
 4-olat
 kalium-2-klor-3- (5- hydroksytetralin-6-yl) -6-okso-5-fenyl-7H-tieno [2,3-b] pyridin-4-
 olat.

2. Farmasøytisk sammensetning omfattende minst en forbindelse ifølge krav 1 og en farmasøytisk akseptabel bærer.

3. Forbindelse ifølge krav 1, for anvendelse i behandlingen av diabetes, metabolsk syndrom, fedme, leversykdom, hepatisk steatose, alkoholfrie fettleversykdom (NAFLD), ikke-alkoholisk steato-hepatitt (NASH), leverfibrose, dyslipidemi, hypertriglyceridemi, hyperkolesterolemi, betennelser, kreft, hjerte- og karsykdommer, åreforkalkning, høyt blodtrykk, retinopatier eller nevropatier.